Play all audios:
Access through your institution Buy or subscribe A novel approach to eliminate residual disease after human leucocyte antigen (HLA)-matched stem cell transplantation (SCT) for leukaemia is
tumour-specific adoptive immunotherapy. Excellent immunotherapeutic targets for adoptive immunotherapy are the haematopoietic system-specific minor-histocompatibility antigens (mHags) HA-1
and HA-2, which are expressed on all normal and malignant haematopoietic cells.1, 2 HA-1 and HA-2 epitopes are presented on the cell surface in the binding groove of HLA-A2 molecules.
Immunotherapy with HA-1 or HA-2-specific cytotoxic T lymphocytes (CTLs) is restricted to leukaemia patients positive for the immunogenic mHag HA-1 or HA-2 alleles, that is HA-1H or HA-2V,
respectively. The mHag status of patients is routinely determined by allele-specific genomic polymerase chain reaction (PCR) on peripheral blood mononuclear cells (PBMCs).2 Generally,
leukaemic cells have the same mHag allelic patterns as the PBMCs. Most leukaemias, however, have karyotypic abnormalities,3 some of which affect mHag encoding genomic regions (e.g. 19p13.3
harbouring the HA-1 gene4 or 7p12-13 harbouring the HA-2 gene5). Here, we have shown as proof of principle that common karyotypic abnormalities in leukaemia cells can knockout mHag encoding
genes and thereby abrogate their recognition by mHag CTLs. This antigen presentation defect is restricted to a very limited number of antigens, namely those affected by the chromosomal
aberration. It differs thereby from previously described immune escape mechanisms like loss/downregulation of HLA expression6 or peptide processing defects,7 which broadly abolish antigen
recognition on malignant cells. Consequently, the observed mechanism of mHag loss requires particular attention when targeting specific mHags with immunotherapy. This is a preview of
subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $259.00 per year only
$21.58 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout
ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * van der Harst D, Goulmy E, Falkenburg J,
Kooij-Winkelaar Y, van Luxemburg-Heijs S, Goselink H _et al_. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. _Blood_
1994; 83: 1060–1066. CAS PubMed Google Scholar * Hambach L, Goulmy E . Immunotherapy of cancer through targeting of minor histocompatibility antigens. _Curr Opin Immunol_ 2005; 17:
202–210. Article CAS Google Scholar * Yunis J, Brunning R . Prognostic significance of chromosomal abnormalities in acute leukemias and myelodysplastic syndromes. _Clin Haematol_ 1986;
15: 597–620. CAS PubMed Google Scholar * den Haan J, Meadows L, Wang W, Pool J, Blokland E, Bishop T _et al_. The minor histocompatibility antigen HA-1: a diallelic gene with a single
amino acid polymorphism. _Science_ 1998; 279: 1054–1057. Article CAS Google Scholar * Pierce R, Field E, Mutis T, Golovina T, von Kap-Herr C, Wilke M _et al_. The HA-2 minor
histocompatibility antigen is derived from a diallelic gene encoding a novel human class I myosin protein. _J Immunol_ 2001; 167: 3223–3230. Article CAS Google Scholar * Brouwer R, van
der Heiden P, Schreuder G, Mulder A, Datema G, Anholts J _et al_. Loss or Downregulation of HLA class I expression at the allelic level in acute leukemia is infrequent but functionally
relevant, and can be restored by Interferon. _Hum Immunol_ 2002; 63: 200–210. Article CAS Google Scholar * Miyazaki M, Akatsuka Y, Nishida T, Fuji N, Hiraki A, Ikeda K _et al_. Potential
limitations in using minor histocompatibility antigen-specific cytotoxic T cells for targeting solid tumor cells. _Clin Immunol_ 2003; 107: 198–201. Article CAS Google Scholar * van Els
C, D'Amaro J, Pool J, Blokland E, Bakker A, van Elsen P _et al_. Immunogenetics of human minor histocompatibility antigens: their polymorphism and immunodominance. _Immunogenetics_
1992; 35: 161–165. Article CAS Google Scholar Download references ACKNOWLEDGEMENTS This work was in part supported by the Dutch Cancer Society and the Deutsche Forschungsgemeinschaft. We
thank Eric Spierings for fruitful discussions. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Immunohaematology and Blood Transfusion, Leiden University Medical Center, Leiden,
The Netherlands L Hambach, J J M Drabbels & Els Goulmy * Department of Haematology, Leiden University Medical Center, Leiden, The Netherlands B A Nijmeijer & J H F Falkenburg Authors
* L Hambach View author publications You can also search for this author inPubMed Google Scholar * B A Nijmeijer View author publications You can also search for this author inPubMed Google
Scholar * J J M Drabbels View author publications You can also search for this author inPubMed Google Scholar * J H F Falkenburg View author publications You can also search for this author
inPubMed Google Scholar * Els Goulmy View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to L Hambach. RIGHTS AND
PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Hambach, L., Nijmeijer, B., Drabbels, J. _et al._ Chromosomal aberrations in leukaemia cells may delete tumour
target antigens of stem cell-based immunotherapy. _Leukemia_ 20, 1298–1300 (2006). https://doi.org/10.1038/sj.leu.2404237 Download citation * Published: 20 April 2006 * Issue Date: 01 July
2006 * DOI: https://doi.org/10.1038/sj.leu.2404237 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link
is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative